Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).

NCT03177239 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT03177239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03177239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Unknown status
Start date
October 19, 2017
Completion date
December 31, 2022
Enrollment
85 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chromophobe renal cell carcinoma, papillary renal cell carcinoma type 1, papillary renal cell carcinoma type 2, renal cell carcinoma, sarcomatoid renal cell carcinoma, xp11 translocation carcinoma